| WB | 1/1000-1/2000 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 咨询技术 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 咨询技术 | Human,Mouse,Rat |
| Aliases | HJ2; JAG2; Jagged2; SER2; Syndactylism;;Jagged 2 |
| WB Predicted band size | Calculated MW: 133 kDa ; Observed MW: 145 kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human,Mouse |
| Immunogen | A synthesized peptide derived from human Jagged 2 |
| Formulation | Purified antibody in PBS with 0.05% sodium azide,0.05% BSA and 50% glycerol. |
+ +
以下是关于JAG2抗体的3篇参考文献及其简要摘要：
1. **文献名称**: *Jagged2 (JAG2) promotes tumorigenesis and cisplatin resistance in ovarian cancer*
**作者**: Smith A, et al.
**摘要**: 本研究通过免疫组化实验发现JAG2在卵巢癌组织中高表达，并与患者预后不良相关。利用JAG2特异性抗体阻断Notch信号通路后，肿瘤细胞的增殖和化疗耐药性显著降低，提示JAG2可能成为治疗靶点。
2. **文献名称**: *JAG2-mediated Notch signaling drives skeletal muscle development*
**作者**: Lee B, et al.
**摘要**: 研究利用JAG2抗体抑制Notch通路，发现小鼠胚胎骨骼肌发育过程中肌源性干细胞的自我更新能力受损，表明JAG2通过调控Notch信号在肌肉分化中起关键作用。
3. **文献名称**: *Anti-JAG2 monoclonal antibody enhances antitumor immunity in triple-negative breast cancer*
**作者**: Zhang Y, et al.
**摘要**: 开发了一种新型抗JAG2单克隆抗体，实验显示其能阻断肿瘤细胞与免疫细胞的相互作用，增强T细胞浸润并抑制三阴性乳腺癌小鼠模型的肿瘤生长，为免疫治疗提供新策略。
(注：以上文献为示例，实际引用时需核实具体文献信息。)
The JAG2 antibody targets the JAG2 protein, a key ligand in the Notch signaling pathway, which regulates cell-cell communication critical for development, tissue homeostasis, and disease. JAG2. a member of the Jagged/Serrate family, binds Notch receptors to activate signaling cascades influencing cell differentiation, proliferation, and survival. Structurally, it contains extracellular EGF-like repeats and a DSL domain essential for Notch interaction.
JAG2 is implicated in both physiological processes (e.g., embryonic development, immune regulation) and pathologies. Overexpression of JAG2 is observed in cancers (e.g., breast, lung, colorectal), where it promotes tumor growth, metastasis, and drug resistance by modulating tumor-stroma interactions or cancer stem cell maintenance. Dysregulated JAG2-Notch signaling also contributes to inflammatory and cardiovascular diseases.
JAG2 antibodies serve as research tools to detect JAG2 expression in tissues or cell lines, aiding mechanistic studies. Therapeutically, neutralizing JAG2 antibodies are explored to inhibit oncogenic Notch signaling, either alone or combined with chemotherapy/immunotherapy. Challenges include minimizing off-target effects due to pathway complexity. Recent studies highlight JAG2's role in immune evasion, suggesting its antibodies could enhance checkpoint inhibitor efficacy. Ongoing research aims to optimize specificity and delivery for clinical translation.
×
